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ABSTRACT: 42 
Aims: The relationship between the renal renin-angiotensin aldosterone system (RAAS) and 43 
cardiorenal pathophysiology is unclear. Our aims were to assess (1) levels of urinary RAAS 44 
components and (2) the association between RAAS components and HbA1c, urine 45 
albumin/creatinine ratio (ACR), estimated glomerular filtration rate (eGFR) and blood pressure 46 
in otherwise healthy adolescents with type 1 diabetes mellitus (TID) vs. healthy controls (HC).  47 
Methods: Urinary angiotensinogen and ACE2 levels, activity of ACE and ACE2, blood pressure 48 
(BP), HbA1c, ACR and eGFR were measured in 65 HC and 194 T1D from the Adolescent Type 49 
1 Diabetes Cardio-Renal Intervention Trial (AdDIT).  50 
Results: Urinary levels of all RAAS components were higher in T1D vs. HC (p<0.0001). Higher 51 
HbA1c was associated with higher urinary angiotensinogen, ACE2, and higher activity of ACE 52 
and ACE2 (p<0.0001, p=0.0003, p=0.003 and p=0.007 respectively) in T1D. Higher ACR 53 
(within the normal range) was associated with higher urinary angiotensinogen (p<0.0001) and 54 
ACE activity (p=0.007), but not with urinary ACE2 activity or ACE2 levels. These observations 55 
were absent in HC. Urinary RAAS components were not associated with BP or eGFR in T1D or 56 
HC.  57 
Conclusions: Otherwise healthy adolescents with T1D exhibit higher levels of urinary RAAS 58 
components compared to HC. While levels of all urinary RAAS components correlate with 59 
HbA1c in T1D, only urinary angiotensinogen and ACE activity correlate with ACR, suggesting 60 
that these factors reflect an intermediary pathogenic link between hyperglycemia and 61 
albuminuria within the normal range. 62 
Key Words: type 1 diabetes, ACE, ACE2, hyperglycemia, albumin to creatinine ratio 63 
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ABBREVIATIONS: 64 
 65 
ACE Angiotensin Converting Enzyme 
ACE2 Angiotensin Converting Enzyme 2 
ACR Albumin to Creatinine Ratio 
AdDIT Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial 
Ang I Angiotensin I 
Ang II Angiotensin II 
BMI Body Mass Index 
BP Blood Pressure 
CV Coefficient of Variation 
DBP Diastolic Blood Pressure 
DM Diabetes Mellitus 
eGFR Estimated Glomerular Filtration Rate 
HbA1c Hemoglobin A1c 
HC Healthy Controls 
HDL cholesterol High-Density Lipoprotein Cholesterol 
HR Heart Rate 
LDL cholesterol Low-Density Lipoprotein Cholesterol 
MAP Mean Arterial Pressure 
NS Not Statistically Significant 
RAAS Renin-Angiotensin Aldosterone System 
SBP Systolic Blood Pressure 
SD Standard Deviation 
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TID Type 1 Diabetes Mellitus 
TID-H Type 1 Diabetes Mellitus - Hyperfiltration 
TID-N Type 1 Diabetes Mellitus - Normofiltration 
T2D Type 2 Diabetes Mellitus 
 66 
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INTRODUCTION: 104 
 105 
While systemic components of the renin-angiotensin aldosterone system (RAAS) are 106 
downregulated in diabetes mellitus (DM) (21), the intrarenal RAAS is activated thereby playing 107 
an important role in the pathogenesis of diabetic nephropathy through increased intraglomerular 108 
pressure and hyperfiltration, and stimulation of tubulointerstitial fibrosis (4). Increased 109 
angiotensinogen produced in the proximal tubule cells is converted to Angiotensin I (Ang I) by 110 
renin (11). Subsequently, the abundance of angiotensin converting enzyme (ACE) in the 111 
proximal tubule cells favours the conversion of Ang I to Ang II. Increased intrarenal Ang II is 112 
associated with diabetic nephropathy in rats (12), which chronically induces hyperfiltration, 113 
proteinuria and injury to glomerular endothelium, basement membrane and podocytes (36). 114 
Angiotensin-converting enzyme 2 (ACE2) is another component of the RAAS that degrades 115 
angiotensin II (Ang II) to the Ang(1-7) fragment (28). Similar to other RAAS components, 116 
ACE2 is highly expressed in the kidney (28).  However, in contrast with Ang II, ACE2 may be 117 
renal protective (41). As reviewed elsewhere, deletion of the Ace2 gene leads to the activation of 118 
oxidative stress pathways (38) and the development of de novo glomerulosclerosis in mice (27) 119 
and pharmacologic inhibition of ACE2 worsens experimental diabetic nephropathy (29). 120 
Given the role of RAAS activation in the pathogenesis of diabetic nephropathy, the 121 
quantification of intrarenal RAAS activation in humans may help to identify patients at higher 122 
risk of renal complications. RAAS components, such as angiotensinogen and ACE2, are 123 
detectable in human urine (19) and serum (33) and urinary enzymatic activity of ACE and ACE2 124 
can also be measured (6). Urinary angiotensinogen is increased in patients with type 2 diabetes 125 
(T2D) compared to healthy controls (HC), and progressively increases as patients transition from 126 
normo- to micro- to macro-albuminuria (25). Similarly, in small studies involving children and 127 
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young adults with type 1 diabetes (T1D) urinary angiotensinogen levels are increased compared 128 
to HC (23, 30). Moreover, angiotensinogen levels in children with T1D are positively associated 129 
with ambulatory blood pressure (30). Urine ACE2 protein and activity levels have also been 130 
shown to be elevated in adults with uncomplicated T1D (6). In the setting of chronic kidney 131 
disease, renal transplant patients with diabetes and patients with heart failure exhibit higher 132 
urinary ACE2 protein levels (14, 33, 39).  In adults with T2D, Park et al have further 133 
demonstrated that urinary ACE2 is increased and independently associated with 134 
microalbuminuria (19). In contrast with what is known in adults, less is known about levels of 135 
urinary RAAS markers or their relationships with glycemic control or renal/cardiovascular 136 
function in cohorts with even earlier subclinical disease, such as in adolescents with T1D. 137 
The objective of this study was to determine if urinary excretion of angiotensinogen and 138 
ACE2 protein, as well as urinary ACE and ACE2 enzymatic activity, is elevated in adolescents 139 
with uncomplicated T1D compared to HC. We hypothesized that urinary excretion of RAAS 140 
markers would be elevated in adolescents with T1D compared to HC and that levels would be 141 
further elevated in T1D patients with renal hyperfiltration (eGFR≥135 ml/min/1.73m2). We also 142 
hypothesized that the highest tertile of ACR within the normal range would be associated with 143 
the highest levels of these RAAS markers.  144 
 145 
RESEARCH DESIGN AND METHODS: 146 
Study Population  147 
This was a cross-sectional study involving patients who were recruited from the 148 
longitudinal, observational, non-interventional arm of the AdDIT, from clinical sites in the 149 
Greater Toronto Area. The Non-Randomized Low-Risk arm of AdDIT is a 4-year 150 
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observational/natural history study, following adolescents at low and medium risk of developing 151 
microalbuminuria (EudraCT Number: 2007-001039-72). High-risk adolescents were recruited 152 
into the AdDIT Interventional Study (http://www.clinicaltrials.gov/ct2/show/NCT01581476), 153 
which was designed to examine the effect of ACE inhibitors and statins on clinical endpoints. 154 
Our cross-sectional study did not include participants involved in the intervention trial. However 155 
as an ancillary component of Non-Randomized Low-Risk arm of AdDIT we also included high-156 
risk subjects who chose not to enter the AdDIT Intervention Study.  157 
A cross-sectional analysis was conducted using the blood and urine samples collected 158 
from 194 T1D and 65 HC participants from the AdDIT trial (1). Inclusion/exclusion criteria have 159 
been described elsewhere (8). In brief, the study population consists of 11 to 16 years old 160 
adolescents inclusively, who achieved a minimum of Tanner stage 2 for puberty and could not be 161 
taking anti-hypertensive or lipid-lowering agents or medications that interfere with the RAAS. 162 
All patients were on a multiple insulin dose regimen or on an insulin pump at the time of the 163 
screening visit. HC were recruited through local advertisements as similar aged volunteers, who 164 
were not on any vasoactive medications, had no previous history of familial hyperlipidemia, 165 
diabetes, obesity, hypertension, or any other significant cardiac, renal or systemic disease and 166 
normal cardiac anatomy and function by screening echocardiogram, as described elsewhere (8). 167 
The Hospital for Sick Children Research Ethics Board, Credit Valley Hospital Ethics Forum and 168 
Markham-Stouffville Research Ethics Board approved the protocol and the consent procedure. 169 
Written informed consent was obtained from the legal guardian/next of kin/caretakers of minors 170 
aged 15 and younger, while the minors provided assent. All subjects aged 16 with capacity to 171 
understand the study information, gave complete written and informed consent to participate in 172 
the study. 173 
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Clinical Assessment 174 
For adolescents with T1D, data on chronological age, age at diabetes onset, and duration 175 
of diabetes were collected. For all subjects, height was measured by a wall-mounted stadiometer 176 
and weight by electronic scales and resting heart rate and right brachial blood pressure was 177 
measured using an age-appropriate cuff and averaging 3 readings with an automated 178 
DINAMAP® sphygmomanometer (Critikon, Tampa, Florida, USA). Systolic and diastolic blood 179 
pressures (SBP and DBP respectively) were also converted to z-scores for age, sex and height. 180 
For all 194 T1D and 65 HC that underwent the same baseline clinical assessment, fasting blood 181 
samples were collected for glucose, HbA1c measurements, lipid profiles (total cholesterol, HDL 182 
[high-density lipoprotein] cholesterol, LDL [low-density lipoprotein] cholesterol and 183 
triglycerides) and serum cystatin C was used to calculate estimated glomerular filtration rate 184 
(eGFR) (8).  185 
 186 
Sample Collection and Analytical Methods  187 
The enzyme activities of urinary ACE2 and ACE were measured using synthetic 188 
substrates as previously reported (39). The amount of ACE2 present in urine specimens was 189 
quantified using a commercial ELISA kit (Cat. No. AG-45A- 0022EK-KI01, AdipoGen, Seoul, 190 
Korea) according to the protocol provided by the supplier (http://www.adipogen.com/ag-45a-191 
0022/ace2-human-elisa-kit.html). A standard curve was generated by performing 1:2 serial 192 
dilutions of human recombinant ACE2 (50 ng/ml), provided with the kit, with the limit of 193 
detection ranging from 0.391 to 25 ng/mL. In preliminary experiments, the average intra-assay 194 
coefficient of variation (CV) for the assay was 2.9%, and the average inter-assay CV was 8.7%. 195 
For urinary angiotensinogen measurements, a commercial ELISA kit was used (Immuno-196 
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Biological Laboratories Co., Ltd., Takasaki-Shi, Gunma, Japan; Code No. 27412), with a 197 
detection limit from 0.313 ng/mL to ~20 ng/mL. In preliminary experiments, the intra-assay CV 198 
was 3.46%, and inter-assay CV was 7.93%. All urinary RAAS measures were corrected for urine 199 
creatinine concentration.  200 
 201 
Renal Assessments  202 
The mean of 2 ACR measures obtained from 2 sets of 3 early-morning urine samples was 203 
obtained and adjusted on a log ACR scale using age, diabetes duration, sex and the coefficients 204 
from the ORPS linear regression model (1). The T1D participants were divided into the 205 
following adjusted ACR tertiles: (1) 64 patients in low ACR tertile (<0.8 mg/mmol), (2) 77 206 
patients in the middle ACR tertile (0.8-1.2 mg/mmol), and (3) 53 patients in the high ACR tertile 207 
(>1.2 mg/mmol). The tertile boundaries were determined based on preliminary data from the 208 
ORPS cohort which predicted the risk for development of microalbuminuria (1). All urine and 209 
blood samples were obtained during the screening phase of the study. As in our previous work, 210 
eGFR was calculated using the Larsson’s formula GFR = 77.24 x Cys C-1.2623, where cystatin C 211 
was measured by laser immunonephelometry (Dade Behring) (8). T1D adolescent participants 212 
were also subdivided into a normofiltration (TID-N) and a hyperfiltration (TID-H) group, where 213 
hyperfiltration was defined as eGFR ≥135 mL/min/1.73m2.   214 
 215 
Statistical Analysis 216 
Normally distributed data are presented as mean ± standard deviation (SD). Non-217 
normally distributed data are presented as median and interquartile range. RAAS markers were 218 
log transformed in order to stabilize the variance. Between-group comparisons of baseline 219 
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parameters in T1D vs. HC groups were made using t-tests for normally distributed data and the 220 
Mann-Whitney U test was used for non-normally distributed data. To determine the association 221 
between the RAAS parameters with blood glucose, HbA1c and ACR, a multivariate regression 222 
analysis was first used. About 30% of patients in our cohort had undetectable RAAS marker 223 
measurements. Replacing a large number of undetectable values with zero could lead to a 224 
downward biased estimate of the slope coefficient in the regression analysis. We therefore used a 225 
TOBIT analysis, which is a censored regression model designed to estimate linear relationship 226 
between variables taking into account the undetectable dependent variable (7). The TOBIT 227 
analysis adjusted for below detection levels of respective RAAS markers along with adjustment 228 
for age, gender, BMI z score, T1D duration and HDL cholesterol (7). Spearman correlation 229 
coefficient was used to determine an association between non-normal outcomes. Statistical 230 
significance was defined as p<0.0125 to account for the effect of multiple comparisons.  All 231 
statistical analyses were performed using SAS v9.4 and GraphPad Prism software (version 5.0).    232 
 233 
RESULTS:  234 
Baseline characteristics  235 
The 194 T1D and 65 HC adolescent participants included in this cross-sectional analysis 236 
from the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) were 237 
normotensive and normoalbuminuric. Baseline parameters, such as gender distribution, age, 238 
blood pressure, eGFR and ACR were similar between HC and T1D adolescents (Table 1). T1D 239 
participants had a higher z-score body mass index compared to HC. Of the 194 T1D patients, 240 
132 exhibited normofiltration (68%) and 62 hyperfiltration (32%). HbA1c, plasma glucose and 241 
plasma HDL cholesterol were higher in T1D compared to HC.  242 
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 243 
Urinary levels of ACE2 and angiotensinogen and enzyme activity of ACE and ACE2 in the HC 244 
and T1D cohorts 245 
Urinary ACE2 activity and urinary ACE2 protein levels, as well as ACE activity and 246 
angiotensinogen were elevated in the T1D group vs. HC (Table 1, Figure 1). There were no 247 
significant differences observed in the RAAS components between the 3 ACR tertiles (Figure 2) 248 
or when comparing T1D-N and T1D-H groups (Figure 3).  249 
 250 
Urinary RAAS markers, plasma glucose and HbA1c in HC and T1D cohorts 251 
In the T1D cohort, higher plasma glucose at the time of urine sample collection 252 
correlated with log urinary ACE activity (β=0.03, p<0.0001) (Table 2). Higher HbA1c was also 253 
correlated with higher log urinary angiotensinogen (β=0.14, p<0.0001), log urinary ACE activity 254 
(β=0.80, p=0.003), log urinary ACE2 activity (β=0.31, p=0.007) and urinary ACE2 levels 255 
(β=0.13, p=0.0003). These associations were significant after correcting for below detection 256 
levels of RAAS markers, age, gender, BMI z-score, T1D duration and HDL cholesterol. None of 257 
the relationships were present in HC. 258 
 259 
The relationship between urinary RAAS components with ACR, renal function and blood 260 
pressure in the T1D and HC cohorts 261 
After correcting for below detection levels of RAAS markers, age, gender, BMI z-score, 262 
T1D duration and HDL cholesterol, higher log ACR levels were correlated with higher log 263 
angiotensinogen (β=0.50, p<0.0001, Table 2) and ACE activity (β=0.26, p=0.007) in T1D 264 
adolescents. In contrast, log ACE2 activity and log ACE2 protein levels were not significantly 265 
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associated with log ACR after correcting for the covariates mentioned above. None of these 266 
relationships were significant in the HC group. Urinary RAAS components were not associated 267 
with eGFR or blood pressure in either group (Table 3).  268 
 269 
DISCUSSION: 270 
 271 
Current methods to identify young patients with T1D at the highest risk of developing 272 
renal and cardiovascular complications remain limited prior to the onset of GFR decline, 273 
microalbuminuria or hypertension. It is perhaps for this reason that untargeted approaches using 274 
available agents such as ACE inhibitors and angiotensin receptor blockers in patients with 275 
uncomplicated disease have been unsuccessful, since the overall risk of complications over 5-10 276 
years remains relatively low. It is therefore important to develop earlier pre-clinical markers of 277 
complications, so that higher risk patients can potentially be identified sooner after diagnosis and  278 
thereby targeted for earlier and perhaps even preventative therapies. It has been reported that the 279 
highest tertile of normoalbuminuria below the threshold for microalbuminuria in adolescents 280 
with T1D may identify a subgroup of patients at higher risk of subsequent progression to 281 
microalbuminria (13). However, the physiological factors that promote these early pre-clinical 282 
changes in urinary albumin excretion remain unclear. 283 
Our first major novel observation in this large cohort of adolescent patients with T1D was 284 
the significantly higher levels of urinary ACE activity, ACE2 activity and ACE2 protein 285 
excretion in the T1D cohort compared to HC. In addition, as reported by Soltysiak et al in 286 
smaller cohort, urinary angiotensinogen levels were significantly higher in adolescents with T1D 287 
compared to HC (30). Previous studies have primarily focused on older patients with T2D, 288 
especially those with established nephropathy, and have reported that these patients have 289 
elevated levels of urinary RAAS markers. Previous reports have also demonstrated elevated 290 
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urinary RAAS mediator excretion rates in adults with T1D compared to HC (6).  Although the 291 
clinical implications of this observation need to be further elucidated, higher levels of urinary 292 
RAAS markers may reflect intrarenal RAAS activation, potentially leading to effects on albumin 293 
excretion as described below. The observation that the urinary excretion of RAAS mediators was 294 
higher in T1D participants is especially important in light of the fact that serum levels of RAAS 295 
are consistently suppressed in patients with diabetes in the context intrarenal RAAS activation – 296 
a phenomenon called “the RAAS paradox” (3, 4, 14). While intrarenal activation of the RAAS 297 
despite low systemic levels is incompletely understood, hyperglycemia increases intrarenal 298 
angiotensinogen expression and angiotensin II levels through heterogeneous nuclear 299 
ribonucleoproteins F and K, reactive oxygen species and hexosamine pathway activation in renal 300 
tubular cells (10, 26, 35). Although we were not able to measure RAAS levels in blood in this 301 
analysis because of small volumes of blood samples taken in children, our results further 302 
reinforce the concept of distinct, directionally opposite levels of RAAS activation in the systemic 303 
circulation compared to the intrarenal compartment – suggesting that urinary levels do not 304 
simply reflect overflow from blood. Nevertheless, since angiotensinogen has a similar molecular 305 
weight as albumin and is also negatively charged, the positive correlation between urinary levels 306 
of angiotensinogen and albumin in adolescents with T1D may be related to similarities in 307 
glomerular handling, leading to increased excretion of both proteins (22). 308 
Our second observation was that higher HbA1c at the time of the urine sample collection 309 
correlated with higher urinary angiotensinogen, ACE activity, ACE2 protein levels and ACE2 310 
activity. Previous in vitro studies have demonstrated a relationship between hyperglycemia and 311 
activation of the RAAS through increased angiotensinogen and renin mRNA expression (11). In 312 
humans, Park et al previously demonstrated that urinary ACE2 levels are associated with 313 
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metabolic parameters such as HOMA-IR and fasting blood glucose (19). Urinary 314 
angiotensinogen and ACE mRNA expression in human renal biopsy tissue are similarly 315 
associated with poor glycemic control in patients with T2D (15, 17). Previous experimental work 316 
has suggested that the glucose-mediated stimulatory effect on angiotensinogen gene expression 317 
in renal proximal tubular cells is mediated by alterations in MAPK signalling, reactive oxygen 318 
species and hexosamine biosynthetic pathways (9). Finally, since pharmacologically-induced 319 
increased glycosuria during clamped euglycemia is associated with higher urinary excretion of 320 
RAAS markers, it is possible that it is the increase in glycosuria rather than hyperglycemia that 321 
increased the urinary excretion of RAAS markers (5). While we could not determine if increased 322 
urinary excretion of RAAS markers was due to the effect of ambient hyperglycemia or the 323 
consequent glycosuria (5), the positive correlation between HbA1c and urinary RAAS markers 324 
suggests a stimulatory effect on the intrarenal RAAS, which may increase albuminuria. 325 
Alternatively, it is possible that injury pathways induced by the diabetic milieu resulted in 326 
increased urinary loss of tubular cells, which express RAAS mediators. Future work should 327 
therefore determine whether or not urinary RAAS mediators reflect ongoing diabetes-related 328 
tubular cell injury (11). 329 
The possible mechanisms leading to increased ACE2 excretion in urine requires 330 
additional comment. Previous work has demonstrated that shedding of ACE2 into the urine is 331 
mediated by ADAM-17, and is stimulated by Ang II and high glucose. This has been shown in 332 
cell culture (40), and the important role of glucose in ACE2 shedding has also been emphasized 333 
in studies in Akita mice in vivo (24).  Therefore the correlation between HbA1C with urinary 334 
ACE2 levels in our dataset fits well with this model linking hyperglycemia with urinary ACE2.  335 
In this regard, the source of urinary ACE2 likely arises from tubular epithelial cells rather than 336 
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systemic filtration, as suggested by experimental studies (37). Future work should consider 337 
simultaneous measurements of blood and urine ACE2 levels to better define the source of 338 
urinary ACE2 excretion. 339 
Our third major observation was that urinary angiotensinogen and ACE activity were 340 
associated with higher levels of albuminuria within the normal range in adolescents with T1D, 341 
while such an association was not observed with urinary ACE2 levels or activity. In animal 342 
models, deletion of the ACE2 gene exacerbates albuminuria, mesangial matrix deposition, 343 
glomerular basement membrane thickening and glomerulosclerosis and administration of human 344 
recombinant ACE2 or ANG-(1-7) reduces albuminuria, blood pressure, renal fibrosis, oxidative 345 
stress and levels of tissue inflammation (27, 29). In humans, previous studies have reported a 346 
significant increase in serum ACE2 activity in male patients with T1D with micro- or 347 
macroalbuminuria compared to HC or normoalbuminuric T1D patients (31). In patients with 348 
T2D and nephropathy, urinary and renal biopsy mRNA expression of ACE and urinary ACE2 349 
levels are also associated with albuminuria (15, 19, 34), and urinary ACE2 levels are elevated in 350 
patients with diabetic nephropathy compared to patients without this complication (14). To our 351 
knowledge, the current report represents the first time that urinary angiotensinogen and ACE 352 
activity have been associated with ACR within the normal range in adolescents with T1D (42). 353 
Consistent with previous studies in other patient cohorts with varying severity of complications, 354 
urinary ACE2 levels and activity were not associated with albuminuria in T1D adolescent 355 
patients without complications (14, 31). Whether the positive correlation between urinary ACE2 356 
and ACR in other patient cohorts with nephropathy, micro- or macroalbuminuria represents a 357 
deleterious effect of ACE2 shedding or instead a compensatory upregulation of this arm of the 358 
RAAS activation cascade in response to ACE-Ang II activation is not known. We hypothesize 359 
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that higher urinary ACE2 levels reflect compensatory activation of this pathway in patients with 360 
complications related to their diabetes, while such pathways are not yet activated in otherwise 361 
healthy patients with diabetes. In future work, it will therefore be important to determine the 362 
relationship between urinary RAAS markers and indices of renal risk over time, including the 363 
markers of tubular injury, the development of microalbuminuria and GFR slope.  364 
 In patients with T2D and baseline renal function impairment, urinary angiotensinogen 365 
and ACE mRNA expression obtained from renal biopsy samples are associated with lower 366 
eGFR; such an association is not seen in patients with preserved renal function (15, 17). Urinary 367 
ACE and ACE2 levels in patients with T2D also correlate with renal function impairment, and 368 
urinary ACE2 is associated with progressive eGFR decline (34). In contrast to previous 369 
observations in cohorts with renal impairment, in our otherwise healthy cohort of adolescents 370 
with T1D, we did not detect a correlation between eGFR and urinary RAAS markers. 371 
Furthermore, and in contrast with experimental models of diabetes (2, 3, 16, 32), patients with 372 
the earliest renal hemodynamic abnormality – renal hyperfiltration – did not exhibit higher levels 373 
of urinary RAAS markers. Therefore, the relationship between urinary RAAS markers and eGFR 374 
may be modified with a longer diabetes duration. 375 
 In light of the relationship between the RAAS and systemic vascular function in patients 376 
with T2D (17), (15), (19), we anticipated that higher levels of RAAS mediators would correlate 377 
with higher blood pressure. In our cohort of normotensive, normoalbuminuric adolescents with 378 
T1D, we did not observe a relationship between any of the RAAS markers and blood pressure or 379 
systemic vascular function. It is therefore tempting to speculate that the relationship between 380 
urinary RAAS markers and blood pressure may be modified over time with a longer duration of 381 
disease – a hypothesis that will be tested during the longitudinal follow up of this cohort.   382 
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Our work has limitations. First, we were only able to measure urinary and not plasma 383 
RAAS mediators, due to the limited volumes obtained in children. Second, our observations 384 
were made in adolescents. As such, we cannot comment about the generalizability of our 385 
findings to adults with preclinical disease, or to adolescent with other medical conditions such as 386 
T2D or other non-diabetic nephropathies. Additionally, although cystatin C based eGFR 387 
measurements may better identify acute changes in kidney function compared to creatinine-388 
based methods (18), cystatin C still tends to underestimate GFR in the higher range compared to 389 
the gold standard inulin clearance based GFR measurement technique (20).  Finally, this was a 390 
cross-sectional study with the analysis performed on samples taken on one occasion. Thus, we 391 
cannot predict changes that occur over time in individual patients and further studies are required 392 
to investigate clinical implications of our observations. 393 
 In conclusion, urinary levels of RAAS mediators are associated with glycemic burden 394 
and urinary angiotensinogen and ACE activity correlate with higher urine ACR. Further work is 395 
required to determine whether urinary RAAS markers can help to identify patients at higher risk 396 
of future renal and cardiovascular complications. 397 
 398 
399 
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Table 1. Baseline demographic characteristics of healthy controls (HC) and type 1 diabetes 587 
adolescent patients (T1D).  588 
Parameter HC (n=65) T1D (n=194) 
   
Baseline demographic parameters   
Males 28 (43%) 97 (50%) 
Age (years) 14.0±2.0 14.4±1.7 
Diabetes duration (years) - 7.2±3.1 
Body mass index (z-score) 0.11±1.14 0.62±0.89a 
 
Baseline biochemistry 
  
Hemoglobin A1c - % (mmol/mol) 5.4±0.2 
(35.3±2.7) 
8.5±1.2 a 
(69.0±13.4) a 
Plasma Glucose (mM) 4.7±0.7 9.7±4.2 a 
Cholesterol (mM) 4.2±0.8 4.3±0.9 
HDL Cholesterol (mM) 1.5±0.3 1.6±0.4 a 
LDL Cholesterol (mM) 2.4±0.7 2.3±0.7 
Triglyceride (mM) 0.9±0.4 0.8±0.3 
   
Renal function assessments   
eGFR (mL/min/1.73 m2) 121±22 129±29 
Urine ACR (mg/mmol) 1.1±1.6 1.0±1.5 
   
Blood Pressure and Heart Rate   
HR (beats per minute) 69±11 67±8 
SBP (mmHg) 111±8 114±9 a 
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DBP (mmHg) 63±5 63±6 
SBP (z-score) 0.04±0.77 0.19±0.87 
DBP (z-score) -0.28±0.71 -0.26±0.64 
   
Urinary RAAS Markers   
Angiotensinogen (ng/mg Cr) 0.7 (0.0-1.8) 2.5 (0.7-6.1) a 
ACE Activity (ng/mg Cr) 0.0 (0.0-0.0) 0.4 (0.0-1.6) a 
ACE2 Activity (ng/mg Cr) 0.0 (0.0-0.0)  79.1 (0.0-418.1) a 
ACE2 (ng/mg Cr) 0.0 (0.0-1.3) 2.7 (0.7-13.1) a 
n, number of participants. a p<0.0125 vs. HC; HC: healthy controls; T1D: type 1 diabetic patients; HR: 589 
heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular 590 
filtration rate; ACR: albumin to creatinine ratio; RAAS: renin-angiotensin aldosterone system; ACE: 591 
angiotensin-converting enzyme; ACE2: angiotensin-converting enzyme 2. 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
601 
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Table 2. Liner regression analysis of log transformed angiotensinogen (A), log ACE 602 
Activity (B), log ACE2 Activity (C) and log ACE2 levels (D) with HbA1c and log 603 
transformed urine albumin to creatinine ratio (ACR) in patients with type 1 diabetes (T1D, 604 
n=194). 605 
(A) Log Angiotensinogen 
 Regression TOBIT 
 β p β p 
Blood Glucose 0.01 NS 0.02 NS 
HbA1c 0.11 <0.0001 0.14 <0.0001 
logACR 0.44 <0.0001 0.50 <0.0001 
 606 
(B) Log ACE Activity 
 Regression TOBIT 
   
 β p β p 
Blood Glucose 0.02 <0.0001 0.03 <0.0001 
HbA1c 0.04 0.011 0.80 0.003 
logACR 0.13 NS 0.26 0.007 
 607 
(C) Log ACE2 Activity 
 Regression TOBIT 
 β p β p 
Blood Glucose 0.04 NS 0.07 NS 
HbA1c 0.21 0.003 0.31 0.007 
logACR 0.61 NS 0.84 NS 
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(D) Log ACE2 
 Regression TOBIT 
 β p β p 
Blood Glucose 0.02 NS 0.02 NS 
HbA1c 0.11 0.0004 0.13 0.0003 
logACR 0.32 0.005 0.30 NS 
NS = not statistically significant. The β coefficients with the associated p value were obtained 608 
from the regression analysis. The adjusted TOBIT analysis was performed to further adjust for 609 
below detection levels of respective RAAS markers, age, gender, BMI z score, T1D duration and 610 
HDL cholesterol(7). 611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
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Table 3: Spearman correlation coefficients (r) and significance levels (p) of associations between urinary RAAS markers and 621 
systemic vascular function in adolescents with type 1 diabetes vs. healthy controls.  622 
HC: healthy controls; T1D: type 1 diabetic patients; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; ACE: 623 
angiotensin-converting enzyme; ACE2: angiotensin-converting enzyme 2.624 
 Angiotensinogen ACE Activity ACE2 Activity ACE2 
HC T1D HC T1D HC T1D HC T1D 
r p r p r p r p r p r p r p r p 
SBP (z-score) 0.11 0.36 -0.040 0.58 0.09 0.49 0.0007 0.99 0.10 0.41 -0.009 0.90 -0.02 0.89 -0.02 0.74
DBP (z-score) -0.05 0.69 -0.11 0.12 0.08 0.53 0.13 0.08 0.06 0.61 0.10 0.16 0.05 0.71 0.10 0.16
HR 0.08 0.52 0.09 0.20 0.22 0.08 0.080 0.27 0.17 0.17 0.03 0.73 0.08 0.54 0.015 0.83
28 
 
LEGEND AND TITLES: 625 
 626 
 627 
Figure 1. Urinary Angiotensinogen (A), ACE Activity (B), ACE2 Activity (C) and ACE2 levels 628 
(D) in healthy controls (HC, n=65) and patients with type 1 diabetes (T1D, n=194). Log 629 
transformed data are represented as median, interquartile range and 10th to 90th percentile.   630 
Figure 2: Angiotensinogen (A), ACE Activity (B), ACE2 Activity (C) and ACE2 levels (D) 631 
levels in HC (n=65) and patients with type 1 diabetes (T1D) in the low ACR tertile 632 
(<0.8mg/mmol, n=64), middle ACR tertile (0.8-1.2mg/mmol, n=77) and high ACR tertile 633 
(>1.2mg/mmol, n=53). Log transformed data are represented as median, interquartile range and 634 
10th to 90th percentile.   635 
Figure 3: Angiotensinogen (A), ACE Activity (B), ACE2 Activity (C) and ACE2 levels (D) 636 
levels in HC (n=65) and patients with type 1 diabetes (T1D) with normofiltration (T1D-N, 637 
GFR<135mL/min/1.73m2, n=132) and hyperfiltration (T1D-H, GFR≥135mL/min/1.73m2, n= 638 
62). Log transformed data are represented as median, interquartile range and 10th to 90th 639 
percentile.   640 
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